The analysis of multiple glioma mRNA expression cohorts from three major glioma related databases, TCGA, CGGA, and Rambrant, revealed that glioma patients with high PCK2 expression (median value threshold) have a poorer prognosis and shorter overall survival compared to those with low PCK2 expression (Log-rank test, P<0.05) (Fig. 1A-E). The gene discussed is PCK2; the disease is central nervous system cancer.